Because these inhibitor pairs did not suppress cancer cell stemness, we aimed to study the effectiveness of a triple drug combination against BRAF, MEK, and EGFR that was used in a clinical trial for patients with BRAFmut colorectal cancer [33]. Here, MAP2K7 is linked to colorectal cancer.